Abhijit A Date

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/774201/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review. Current Neuropharmacology, 2022, 20, 799-808.	1.4	7
2	Coumarinolignans with Reactive Oxygen Species (ROS) and NF-κB Inhibitory Activities from the Roots of Waltheria indica. Molecules, 2022, 27, 3270.	1.7	3
3	Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer. Drug Delivery and Translational Research, 2021, 11, 2085-2095.	3.0	3
4	<i>In vitro</i> efficacy of anthelmintics on <i>Angiostrongylus cantonensis</i> L3 larvae. Parasitology, 2021, 148, 240-250.	0.7	9
5	<i>In Vitro</i> Release Testing of Acyclovir Topical Formulations Using Immersion Cells. Assay and Drug Development Technologies, 2021, 19, 75-84.	0.6	6
6	Synthesis and Characterization of Lipophilic Salts of Metformin to Improve Its Repurposing for Cancer Therapy. ACS Omega, 2021, 6, 2626-2637.	1.6	14
7	Ion-Complex Microcrystal Formulation Provides Sustained Delivery of a Multimodal Kinase Inhibitor from the Subconjunctival Space for Protection of Retinal Ganglion Cells. Pharmaceutics, 2021, 13, 647.	2.0	10
8	An ionâ€paired moxifloxacin nanosuspension eye drop provides improved prevention and treatment of ocular infection. Bioengineering and Translational Medicine, 2021, 6, e10238.	3.9	9
9	Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 66-74.	2.0	18
10	Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, and <i>in Vitro</i> Activity against <i>Cryptococcus neoformans</i> . ACS Infectious Diseases, 2021, 7, 2637-2649.	1.8	11
11	DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. Cancers, 2021, 13, 4889.	1.7	4
12	BX795-Organic Acid Coevaporates: Evaluation of Solid-State Characteristics, In Vitro Cytocompatibility and In Vitro Activity against HSV-1 and HSV-2. Pharmaceutics, 2021, 13, 1920.	2.0	5
13	Development of Nanoemulsion Preconcentrate of Capsanthin with Improved Chemical Stability. Assay and Drug Development Technologies, 2020, 18, 34-44.	0.6	9
14	Fenugreek Leaf Extract and Its Gel Formulation Show Activity Against <i>Malassezia furfur</i> . Assay and Drug Development Technologies, 2020, 18, 45-55.	0.6	13
15	Pharmaceutically Acceptable Carboxylic Acid-Terminated Polymers Show Activity and Selectivity against HSV-1 and HSV-2 and Synergy with Antiviral Drugs. ACS Infectious Diseases, 2020, 6, 2926-2937.	1.8	11
16	Gelling hypotonic polymer solution for extended topical drug delivery to the eye. Nature Biomedical Engineering, 2020, 4, 1053-1062.	11.6	69
17	Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 138, 23-29.	2.0	17
18	Development and evaluation of taste masked dry syrup formulation of potassium chloride. AAPS Open, 2019, 5, 1.	0.4	7

ΑβΗΙJIΤ Α DATE

#	Article	IF	CITATIONS
19	Development of a mucoinert progesterone nanosuspension for safer and more effective prevention of preterm birth. Journal of Controlled Release, 2019, 295, 74-86.	4.8	31
20	Single-step and low-energy method to prepare solid lipid nanoparticles and nanostructured lipid carriers using biocompatible solvents. European Journal of Pharmaceutical Research, 2019, 1, 12-19.	1.0	6
21	Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
22	Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials, 2018, 185, 97-105.	5.7	74
23	Local enema treatment to inhibit FOLH1 /GCPII as a novel therapy for inflammatory bowel disease. Journal of Controlled Release, 2017, 263, 132-138.	4.8	20
24	MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound. Journal of Controlled Release, 2017, 263, 120-131.	4.8	95
25	Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2017, 23, 6592-6601.	3.2	43
26	Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 3633-3639.	1.4	48
27	Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. Journal of Controlled Release, 2016, 240, 504-526.	4.8	332
28	Natural polyphenols: potential in the prevention of sexually transmitted viral infections. Drug Discovery Today, 2016, 21, 333-341.	3.2	26
29	Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection. Journal of Biomedical Nanotechnology, 2015, 11, 416-427.	0.5	33
30	Development and validation of a simple and isocratic reversedâ€phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates. Biomedical Chromatography, 2015, 29, 709-715.	0.8	7
31	Cationic nanoemulsions as potential carriers for intracellular delivery. Saudi Pharmaceutical Journal, 2015, 23, 188-194.	1.2	30
32	Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathogens, 2015, 11, e1005075.	2.1	60
33	Celecoxib nanosuspension: single-step fabrication using a modified nanoprecipitation method and in vivo evaluation. Drug Delivery and Translational Research, 2014, 4, 365-376.	3.0	14
34	Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV Type 1 Treatment. AIDS Research and Human Retroviruses, 2013, 29, 746-754.	0.5	69
35	A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials, 2013, 34, 6202-6228.	5.7	75
36	Design, Characterization and Evaluation of Anti-epileptic Activity of Nanoprecipitating Preconcentrate of Carbamazepine. Drug Delivery Letters, 2013, 3, 61-69.	0.2	4

ΑβΗΙJIΤ Α DATE

#	Article	IF	CITATIONS
37	Translating Nanotechnology from Bench to Pharmaceutical Market: Barriers, Success, and Promises. Journal of Drug Delivery, 2012, 2012, 1-2.	2.5	7
38	Overcoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations. Drug Discovery Today: Technologies, 2012, 9, e87-e95.	4.0	144
39	Characterization of Soy Polysaccharide and Its In Vitro and In Vivo Evaluation for Application in Colon Drug Delivery. AAPS PharmSciTech, 2012, 13, 934-943.	1.5	15
40	Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Research, 2012, 96, 430-436.	1.9	85
41	Lecithin-Based Novel Cationic Nanocarriers (Leciplex) II: Improving Therapeutic Efficacy of Quercetin on Oral Administration. Molecular Pharmaceutics, 2011, 8, 716-726.	2.3	90
42	Lecithin-based novel cationic nanocarriers (LeciPlex) I: fabrication, characterization and evaluation. Nanomedicine, 2011, 6, 1309-1325.	1.7	26
43	Sulfobutyl Ether7 β-Cyclodextrin (SBE7 β-CD) Carbamazepine Complex: Preparation, Characterization, Molecular Modeling, and Evaluation of In Vivo Anti-epileptic Activity. AAPS PharmSciTech, 2011, 12, 1163-1175.	1.5	69
44	Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery. Nanotechnology, 2011, 22, 275102.	1.3	49
45	Eudragit EPO Nanoparticles: Application in Improving Therapeutic Efficacy and Reducing Ulcerogenicity of Meloxicam on Oral Administration. Journal of Biomedical Nanotechnology, 2011, 7, 590-597.	0.5	33
46	Nanosuspensions: a promising drug delivery strategy. Journal of Pharmacy and Pharmacology, 2010, 56, 827-840.	1.2	663
47	Novel delivery systems of atorvastatin should be evaluated for pharmacodynamics instead of pharmacokinetics. Journal of Pharmacy and Pharmacology, 2010, 59, 1583-1584.	1.2	10
48	Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine, 2010, 5, 1595-1616.	1.7	360
49	Tween 80â^'Sodium Deoxycholate Mixed Micelles: Structural Characterization and Application in Doxorubicin Delivery. Journal of Physical Chemistry B, 2010, 114, 16414-16421.	1.2	96
50	Parenteral microemulsions: An overview. International Journal of Pharmaceutics, 2008, 355, 19-30.	2.6	157
51	Design and Evaluation of Microemulsions for Improved Parenteral Delivery of Propofol. AAPS PharmSciTech, 2008, 9, 138-145.	1.5	51
52	Potential of Cyclodextrin Complexation and Liposomes in Topical Delivery of Ketorolac: In Vitro and In Vivo Evaluation. AAPS PharmSciTech, 2008, 9, 1165-1170.	1.5	14
53	Microemulsions: Applications in Transdermal and Dermal Delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 2007, 24, 547-596.	1.2	39
54	Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetilâ~†. International Journal of Pharmaceutics, 2007, 329, 166-172.	2.6	310

Αβηιστά Α Ολτε

#	Article	IF	CITATIONS
55	Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. International Journal of Pharmaceutics, 2007, 345, 163-171.	2.6	304
56	Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticlesâ~†. Advanced Drug Delivery Reviews, 2007, 59, 505-521.	6.6	248
57	HPTLC Determination of Cefpodoxime Proxetil in Formulations. Chromatographia, 2007, 66, 905-908.	0.7	5
58	Exploring the potential of N-methyl pyrrolidone as a cosurfactant in the microemulsion systems. International Journal of Pharmaceutics, 2006, 326, 186-189.	2.6	16
59	Novel Drug Delivery Systems: Potential in Improving Topical Delivery of Antiacne Agents. Skin Pharmacology and Physiology, 2006, 19, 2-16.	1.1	86
60	Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clinical Interventions in Aging, 2006, 1, 327-348.	1.3	349
61	Current strategies for engineering drug nanoparticles. Current Opinion in Colloid and Interface Science, 2004, 9, 222-235.	3.4	136
62	Microemulsions: Pharmaceutical Applications. , 0, , 259-301.		3